Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532573 | 0.89 | KDM4E (0.64) | ADRA1BDRD2HTR2AHTR1AHTR7 | |
| Umespirone SCHEMBL678458 | 0.86 | DRD2 (0.69) | ADRA1BDRD2HTR2AHTR1AHTR7 | |
| SCHEMBL10631261 | 0.85 | HTR1A (0.58) | ADRA1BDRD2HTR2AHTR1AHTR7 | |
| SCHEMBL13532577 | 0.82 | HTR1A (0.64) | ADRA1BDRD2HTR2AHTR1AHTR7 | |
| SCHEMBL13532574 | 0.81 | HTR1A (0.58) | ADRA1BDRD2HTR2AHTR1AHTR7 | |
| SCHEMBL10785287 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2ADRA1BDRD2HTR2AHTR1A | |
| SCHEMBL13532575 | 0.79 | KDM4E (0.63) | DRD2HTR2AHTR1AHTR7DRD4 | |
| Hydrochloric Acid SCHEMBL10783574 | 0.78 | SMN1; SMN2 (0.68) | SMN1; SMN2ADRA1BDRD2HTR2AHTR1A | |
| SCHEMBL6474505 | 0.77 | DRD2 (0.60) | SMN1; SMN2ADRA1BDRD2HTR2AHTR1A | |
| SCHEMBL13484830 | 0.76 | HTR1A (0.71) | ADRA1BDRD2HTR2AHTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | NR5A2, NR4A3, NR4A2 | SMN1; SMN2 2985/4885ADRA1B 233/4885DRD2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.